Genmab A/S balance sheet GNMSF

Annual Quarterly

As of Dec 31, 2025, Genmab A/S had total assets of $12.9 billion and total liabilities of $7.0 billion. Stockholders' equity was $5.8 billion. It held $1.7 billion in cash and investments against $5.4 billion of total debt, net debt of $3.7 billion. The current ratio, current assets divided by current liabilities, was 2.02.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line
FY 2025
Dec 31, 2025
Assets
Cash
1,715
Cash and investments
1,715
Receivables
1,112
Inventory
18
Total current assets
2,885
Property and equipment, net
153
Goodwill
355
Total assets
12,873
Liabilities and equity
Total current liabilities
1,427
Total liabilities
7,026
Stockholders' equity
5,847
Debt
Debt due within a year
273
Long-term debt
5,001
Lease liabilities
152
Total debt
5,426
Net cash
-3,711
Ratios
Current ratio
2.02x
Debt to equity
0.93x
Return on equity
16.47%
Return on assets
7.48%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
GMAB (Nasdaq), GNMSF (OTC)
Headquarters
1253 Copenhagen K, Denmark
SEC filer status
Large accelerated filer
SEC CIK
1434265

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.